Online Only Articles

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
Department of Pathology, Memorial Sloan Kettering Cancer Center, USA
Driskill Graduate Program in Life Sciences, Feinberg School of Medicine, Northwestern University, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA;Gerstner Sloan Kettering Graduate School of Biomedical Sciences, and Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, USA
Center for Epigenetics Research Memorial Sloan Kettering Center, USA
Department of Pathology, Memorial Sloan Kettering Cancer Center, USA
Cardiology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, USA
Department of Surgery, Memorial Sloan Kettering Cancer Center, USA
Department of Surgery, Memorial Sloan Kettering Cancer Center, USA
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
Department of Medicine, Columbia University Medical Center, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA;Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
Vol. 103 No. 1 (2018): January, 2018 https://doi.org/10.3324/haematol.2017.177600